BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Antengene and MSD Enter Global Clinical Collaboration to Evaluate ATG-022 and KEYTRUDA® Combo in Solid Tumors

Antengene Corporation Limited , a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercial...

May 21, 2025 | News

Xuanzhu Biopharmaceutical’s Bireociclib (Xuanyuening®) Approved in China, Setting New Benchmark in HR+/HER2- Breast Cancer Treatment

National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade...

May 19, 2025 | News

Agilent and Ubix Therapeutics Join Forces to Advance Targeted Cancer Therapies in South Korea

Research focuses on targeted protein degradation and antibody-drug conjugate as promising modalities for developing next-generation cancer therapies ...

May 15, 2025 | News

Hyundai ADM Bio Withdraws IND for Penetrium™/Docetaxel and Pivots to Immunotherapy Combinations

Hyundai ADM Bio announced the voluntary withdrawal of its Investigational New Drug (IND) application for Phase 1 clinical trial evaluating Pene...

May 14, 2025 | News

Gene Solutions Validates K-TRACK™ ctDNA Test as Prognostic Biomarker

Gene Solutions, a biotechnology company dedicated to advancing precision oncology in Asia, is excited to announce the publication of a pioneering real-worl...

May 12, 2025 | News

Nutshell Therapeutics Receives FDA IND Clearance for First-in-Human Trial of NTS071 Targeting p53 Y220C Mutation

Nutshell Therapeutics ( Shanghai ) Co., LTD. received IND clearance from the FDA to initiate Phase 1 clinical ...

May 05, 2025 | News

TAE Life Sciences and Ohio State Forge Landmark BNCT Partnership to Advance Next-Generation Boron-Based Cancer Therapies

TAE Life Sciences (TLS) announced the signing of a Letter of Intent to collaborate with The Ohio State University Comprehensive Cancer Center – ...

May 05, 2025 | News

Merck to Acquire SpringWorks Therapeutics for $3.9 Billion, Strengthening Rare Tumor Leadership

Purchase price of $47 per share in cash represents an enterprise value of €3.0 billion ($3.4 billion), or an equity value of approximately $3.9 bill...

April 28, 2025 | News

Primo Biotechnology Secures PIC/S GMP and GDP Certifications, Strengthening Global Position in Nuclear Medicine

Primo Biotechnology Co., Ltd. ("Primo") proudly announces that its Taoyuan pharmaceutical facility has successfully passed inspection by Taiwan Food and Dr...

April 25, 2025 | News

GC Cell Secures Exclusive Rights to DAAN Biotherapeutics’ Tumor Antigen-Specific Antibody for CAR-T and CAR-NK Therapies

DAAN Biotherapeutics, a leading innovative drug development company specializing in T-Cell receptor (TCR)-based therapies, has signed an exclusi...

April 22, 2025 | News

TGA Approves IFINWIL® for High-Risk Neuroblastoma Treatment in Australia

Norgine is pleased to announce that the Australian Therapeutic Goods Administration (TGA) has approved the registration of IFINWIL® (eflornit...

April 17, 2025 | Regulatory

Clarity Begins Phase II Dosing in SECuRE Trial for Prostate Cancer with Enhanced 67Cu-SAR-bisPSMA Formulation

The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of the SECuRE trial has been treated with their first dose of 8 GB...

April 16, 2025 | News

Bristol Myers Squibb’s Opdivo Plus Yervoy Wins FDA Nod as First-Line Treatment for Advanced Liver Cancer

Bristol Myers Squibb announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab) plus Yervoy® ...

April 14, 2025 | News

Lucence and HKPOS Launch Hong Kong’s First Study on Blood Test for Early Lung Cancer Detection

In a two-year collaboration with HKPOS, 600 lung cancer patients aged 45-74 in Hong Kong will be studied using Lucence's non-invasive liquid biopsy to as...

April 10, 2025 | News

Stay Connected